spacer
home > ebr > Summer 2018
PUBLICATIONS

European Biopharmaceutical Review

ebr
Summer 2018

   
Text
PDF
Editor’s Letter

EBR Editor Dr Deborah O’Neil details the history of diabetes treatments and how they have changed over the last eight decades, while also summarising the themes covered by the issue’s authors.
 
view
download pdf
Science and Innovation
In Brief

Natural Intelligence Looks at AI

EBR's Industry Advisor, Emile Bellott, assesses how the biopharmaceutical industry and human health can benefit from the use of artificial intelligence.
 
view
download pdf
bullet
PATENTING POLICY AND PRACTICE
Considerations for Protecting and Launching Biosimilars

Patenting Biosimilars

A streamlined process is enabling generics companies to enter the market with a biosimilar product and gain approval quicker than ever before, as explained by Jennifer O’Farrell at Boult Wade Tennant.
 
view
download pdf
Biosimilar Applications

The Patent Dance

Sanya Sukduang and Thomas J Sullivan at Finnegan detail how biosimilar applicants can now bypass the usual lengthy information exchange after the introduction of new biologics licensing rules.
 
view
download pdf
bullet
Mass Spectrometry
Primary Sequence Analysis

Understanding Biosimilars

Amino acid sequencing relies on state-of-the-art technology to deliver the best possible analytics, though the mass spectrometry involved can be problematic, as discussed by Dr Richard Easton and Dr Andrew Reason at BioPharmaSpec.
 
view
download pdf
Monitoring with Mass Spectrometry

Driving Discovery

EBR asked Dr Simon Cubbon at Thermo Fisher Scientific about the benefits of using a mass spectrometry-based multi-attribute method in drug development.
 
view
download pdf
Probing Pathology with MALDI

Visualising Alzheimer’s

Dr Shannon Cornett at Bruker Daltonics suggests the ways in which ultra-high resolution mass
spectrometry imaging techniques can be advantageous in understanding neurological disorders.
 
view
download pdf
bullet
Orphan Drugs
Gene Therapy

End of the Tunnel

Dr Serge Braun at AFM-Téléthon examines the ever-changing climate of gene therapy technologies and how they are applied and outlines the limitations that they may present.
 
view
download pdf
bullet
Analytical Tools
Monoclonal Antibody Innovations

Enhancing Analysis

A growing need for rapid high-throughput analysis of biotherapeutics results in the necessity of standardised chromatographic methods, as told by Dr Amy Farell,Dr Sara Carillo, and Dr Jonathan Bones at the National Institute of Bioprocessing Research and Training.
 
view
download pdf
bullet
Genomics and DNA
Red Biotechnology

Endonuclease Compliance

New enzyme derivatives are being welcomed across the biopharmaceuticals industry following easier red biotechnology applications, as illustrated by Dr Pablo Domínguez de María on behalf of c-LEcta and Dr Stefan Schoenert at c-LEcta.
 
view
download pdf
RPA Development

Technique Transition

Dr Olaf Piepenburg at TwistDx explores the advantages of recombinase polymerase amplification, which is growing in popularity as an alternative to traditional polymerase chain reactions for testing outside the laboratory.
 
view
download pdf
Tumour Heterogeneity

Alternative Approaches

Dr Ute Boronowsky at Oxford Genetics introduces a new gene editing tool that has been developed to iron out issues often encountered during single-cell analysis.
 
view
download pdf
bullet
Biosimilars
Diabetes Biosimilars

Calibrating Expectations

Rafal Kokolus, Dr Doug Niven, and Rohit Sood at Syneos Health claim that diabetes treatments could change following the increasing incorporation of biosimilars as an alternative therapeutic.
 
view
download pdf
bullet
ADCs as Therapeutics
ADC Development

Targeted Treatment

Given the rise in usage of antibody-drug conjugates in cancer therapy, addressing the problems they sometimes present is important. Edward Barnes, Dr David Bunka, and Dr Arron Tolley at Aptamer Group demonstrate how aptamers can help alleviate these.


 
view
download pdf
Advancing ADC Technology

The Future of ADCs

Changed approaches and new technologies in the drugs’ development sector has given rise to improved and innovative targeted drugs, as explained byDr Neil Butt at IONTAS.
 
view
download pdf
Targeted Therapies

Engineering Antibodies

Targeted antibodies are always evolving, though the challenges they often come with still remain. Professor Andreas Pahl at Heidelberg Pharma illustrates the ways in which these can be overcome.
 
view
download pdf
   
spacer


Published quarterly in
January, April,
July, and October

News and Press Releases

Merck to Provide BioReliance® End-to-End Solutions to Phanes Therapeutics

• Collaboration to accelerate development and manufacturing of Bispecific Antibody • Merck plans to offer Phanes a full suite of products and services under its BioReliance® offering
More info >>

White Papers

Soothing the Logistical Headache of Clinical Trials

Equilibrium Travel Management

As many as 30 per cent of subjects on phase three clinical studies drop out.  Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial.  It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >>

Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement